Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 +5.22 (+3.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
70 71 Next >
2 Struggling Dividend Growth Stocks That Could Make You Richer
Let's look beyond these drugmakers' ongoing issues. 
Via The Motley Fool
Why Dividend Stocks Should Be a Key Part of Your Retirement Plan
You can collect the dividend income while keeping your original investment intact. 
Via The Motley Fool
The 7 Best Long-Term Stocks to Buy in July
Although it might not be the most exciting approach, the best long-term stocks in July offer a greater chance of upside success. 
Via InvestorPlace
Is AbbVie's Dividend Yield Safe?
With biosimilar competition ramping up, the drugmaker's free cash flows are poised to shrink this year. 
Via The Motley Fool
Got $5,000? These Are 3 of the Best Stocks to Buy in July
There's something here for dividend, value, and growth investors. 
Via The Motley Fool
The 7 Best Forever Stocks to Buy for July 2023
With the market throwing some curveballs, investors may find more confidence engaging the best forever stocks to buy. 
Via InvestorPlace
Why Shares of Alvotech Are Jumping Friday
The biosimilar drug company's shares rebounded a day after it announced that the FDA had dealt it setback. 
Via The Motley Fool
This Is What Whales Are Betting On AbbVie
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis. 
Via Investor's Business Daily
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult... 
Via Benzinga
3 Spectacular Dividend Stocks to Buy in July
Heat up your portfolio this month with these dividend stocks. 
Via The Motley Fool
Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys
Both companies are facing significant patent cliffs, but they've been preparing for this moment. 
Via The Motley Fool
3 Magnificent Dividend Stocks to Buy Hand Over Fist in July
These dividend stocks can add some fireworks to income investors' portfolios. 
Via The Motley Fool
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer. 
Via The Motley Fool
Why Are Immunome Shares Trading Higher Today
Immunome Inc (NASDAQ: IMNM) and Morphimmune have announced a merger agreement in  
Via Benzinga
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
10 Stocks You Can Buy Right Now With Dividend Yields of Over 4%
Income investors could love these high-yield stocks. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023
Investors looking to buy low and eventually sell high would be smart to take a position with one or more of these pharma stocks. 
Via InvestorPlace
Why This BeiGene Analyst Slashes Forecast By Almost 42%
BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks. 
Via Benzinga
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Bausch + Lomb Corporation (NYSE: BLCO) has agreed to acquire 'front of eye' ophthalmology assets for $1.75 billion in upfront cash, plus additional milestone payments from Novartis AG (NYSE: 
Via Benzinga
7 Best Dividend Stocks to Buy Now in July 2023
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. 
Via The Motley Fool
5 High-Yielding Dividend Stocks That Are Bargain Buys
This is a good time for investors to load up on healthcare companies. 
Via The Motley Fool
7 Top Growth Stocks to Watch for H2 2023
Many growth stocks still haven't completely recovered from their 2022 losses, so they have plenty of opportunities to do so in H2 2023. 
Via InvestorPlace
Six Weeks In, AI Outpaces Wall Street's Elite: The ChatGPT Challenge
Via Benzinga
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab... 
Via Benzinga
7 Stocks That Every 40-Year-Old Should Buy Today
Having reached the halfway point in life, make your market moves count with the best investments for 40-year-olds. 
Via InvestorPlace
3 Penny Stocks with Multibagger Potential for the Second Half of 2023
If you have patience and a high risk tolerance, here are three penny stocks to watch in 2023 for their multibagger potential. 
Via InvestorPlace
Why Mutual Fund Darling And Top 1% Stock MoonLake Immunotherapeutics Nearly Doubled
The company is treating a painful skin condition and could go up against AbbVie. 
Via Investor's Business Daily
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
70 71 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.